Search for: [Abstract = "k, most commonly every 6\-7 week. Two hours before the injection of the labelled somatostatin analogue, the infusion of amino\-acids formula was given to every patient for nephroprotection. The infusion time of the pre\-prepared somatostatin analogue preparation labelled with radioisotope \(manufacturer\: Research and Development IAE Radioisotope Centre Otwock\-Świerk\) was 30 minutes. It was followed by 6\-hour infusion of the amino\-acids. The NHL patients received the dose of 90Y\-Ibritumomab\-tiuxetan \(Zevalin\) calculated based on the platelet count and body mass. If the platelet count \(PLT\) exceeded 150 000 per µl, the patient was administered 15 MBq \(0,4 mCi\) per kg of the body mass. If the PLT was within the range 100 000 – 150 000 per µl, the dose of 11 MBq \(0,3 mCi\) per kg of the body mass was given. The maximum dose was 1200 MBq \(32 mCi\). The radioimmunotherapy was preceded by Rituximab injection \(250 mg per m2 of the BSA\) administered one week earlier. Rituximab injection \(the dose of 250 mg per m2 of the BSA\) was repeated again 4 hours before the treatment with Zevalin. The preparation was labelled with Yttrium isotope in Nuclear Medicine Unit of the Endocrinology Department of University Hospital in Krakow. The radiochemical purity of the pharmaceutical was assessed after the labelling procedure, Zevalin was injected only when its purity was higher than 95%. Every patient w"]

Number of results: 1